Comparison of Diluted Insulin (U10) Versus Standard (U100) Insulin in Automated Insulin Delivery Systems: Reducing Time Below Range in Young Children

Extended Use of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 1 Diabetes: 12‐Month Extension of a Randomized Controlled Trial

The Omnipod 5 Automated Insulin Delivery (AID) System is safe and effective for individuals managing Type 1 diabetes (T1D). Longer‐term studies may provide additional evidence of sustained effectiveness and safety of AID system use in T1D.

Insulin Efsitora Demonstrates Similar Efficacy and Safety Profiles to Insulin Icodec in Insulin‐Experienced Individuals With Type 2 Diabetes Mellitus: Matching‐Adjusted Indirect Comparisons of QWINT‐3 Versus ONWARDS 2, and QWINT‐4 Versus ONWARDS 4

To conduct indirect treatment comparisons (ITCs) of insulin efsitora alfa (efsitora) versus insulin icodec (icodec) in insulin‐experienced individuals with Type 2 Diabetes Mellitus.

Commercial Automated Insulin Delivery Systems in Type 1 Diabetes Pregnancy: Protocol for a Mixed‐Methods Systematic Review and Meta‐Analysis of Glycaemic, Perinatal, Psychosocial and Implementation Outcomes

Commercial automated insulin delivery (AID) systems are increasingly used in pregnancies complicated by Type 1 diabetes, but the evidence is dispersed across trials, observational studies, case series and qualitative research. Existing syntheses have largely emphasised glycaemic efficacy and selected perinatal outcomes...

Once-weekly insulin icodec (Awiqli) for type 2 diabetes.

Insulin icodec (Awiqli – Novo Nordisk), an ultra-long-acting basal human insulin analog, has been approved by the FDA for once-weekly treatment of type 2 diabetes. Two long-acting insulin analogs are available in the US for once-daily use: glargine and degludec (see Table 1). Insulin icodec has been available in Canada...

Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST‐T1D Extension Study

To evaluate changes in glycaemic control following semaglutide discontinuation in adults with Type 1 diabetes and obesity who completed the ADJUST‐T1D randomised controlled trial.

World Journal of Clinical Pediatrics